Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2002

View Archived Issues

Drug pipeline for anxiety

Thalidomide plus temozolomide in malignant gliomas

Good tolerability profile reported for tetracycline COL-3 in high-grade glioma

EMD-121794 reported to be well tolerated in patients with malignant gliomas

Enzyme-inducing anticonvulsants improve tolerability of CCI-779 in patients with CNS tumors

Improved tolerability of PZA in glioblastoma multiforme patients receiving anticonvulsants

Tolerability of intratumoral DTI-015 in recurrent malignant glioma

T-138067 inactive in astrocytoma and glioblastoma multiforme

Promising data reported for dendritic cell vaccine in GBM

Boston Scientific acquires Smart Therapeutics

Bayer describes inhibitors of PDE7B for asthma and bone disorders

Novel nicotinic acetylcholine and/or 5-HT receptor ligands covered by Merck patent

Two series of cytokine production inhibitors with utility in arthritis and heart failure

New CRF antagonists under study at GSK

BMS designs new series of PDE7 inhibitors

Sankyo scientists prepare benzopyran compounds with multiple mechanisms of action

Senju claims novel compounds with potential in reflux esophagitis

Encouraging results from phase II trial with IP-751 in neuropathic pain

Solvay acquires exclusive worldwide rights to cetrorelix

Preclinical efficacy of Cerebragel in brain cancer

Organon and Entelos expand research collaboration

FDA approves Pegasys and Copegus combination therapy in hepatitis C

Swissmedic approves Glivec for first-line treatment of CML

Celltech returns rights to CF program to Targeted Genetics

Allos to begin rolling NDA submission for RSR-13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.